For the third year in a row, the percentage of U.S. kindergarteners with a vaccine exemption has grown, this time to 2.2%.
Here is some other vaccine news of note for the week.
Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.
Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.
Vaxart touted phase 2 data for its oral flu vaccine candidate in a trial against Sanofi's market-leading Fluzone.
The U.S. age expansion will add fuel to the HPV shot's already fast-growing sales, which analysts predict will reach $3.28 billion in 2024.
Roswell Park Comprehensive Cancer Center has announced a biotech joint venture with Havana-based Center for Molecular Immunology.
The organizations saw the article’s method as problematic, as it relies solely on suspected adverse reactions reports received from different geographies.
In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.
